IL270097B2 - Cd 14 antagonist antibodies for treating neurodegenerative diseases - Google Patents
Cd 14 antagonist antibodies for treating neurodegenerative diseasesInfo
- Publication number
- IL270097B2 IL270097B2 IL270097A IL27009719A IL270097B2 IL 270097 B2 IL270097 B2 IL 270097B2 IL 270097 A IL270097 A IL 270097A IL 27009719 A IL27009719 A IL 27009719A IL 270097 B2 IL270097 B2 IL 270097B2
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- seq
- sequence
- antagonist antibody
- cdr3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901462A AU2017901462A0 (en) | 2017-04-21 | Agents for treating or preventing motor neurone disease and uses therefor | |
| AU2018900762A AU2018900762A0 (en) | 2018-03-08 | “agents for treating disease and uses therefor” | |
| PCT/AU2018/050357 WO2018191786A1 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270097A IL270097A (enExample) | 2019-12-31 |
| IL270097B1 IL270097B1 (en) | 2024-01-01 |
| IL270097B2 true IL270097B2 (en) | 2024-05-01 |
Family
ID=63855469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270097A IL270097B2 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
| IL309046A IL309046B2 (en) | 2017-04-21 | 2018-04-20 | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309046A IL309046B2 (en) | 2017-04-21 | 2018-04-20 | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200148780A1 (enExample) |
| EP (1) | EP3612566A4 (enExample) |
| JP (2) | JP2020517740A (enExample) |
| KR (1) | KR20200015477A (enExample) |
| CN (1) | CN110831975A (enExample) |
| AU (1) | AU2018255489B2 (enExample) |
| IL (2) | IL270097B2 (enExample) |
| WO (1) | WO2018191786A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217916A1 (en) * | 2018-05-10 | 2019-11-14 | The Methodist Hospital | Methods for prognosis and management of disease |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| TWI877170B (zh) * | 2019-06-11 | 2025-03-21 | 美商阿列克特有限責任公司 | 抗揀選蛋白抗體之使用方法 |
| JP2022541646A (ja) * | 2019-07-25 | 2022-09-26 | インプリシット・バイオサイエンス・リミテッド | 急性神経炎症傷害を処置するための方法および薬剤 |
| CN115103676A (zh) * | 2020-02-13 | 2022-09-23 | 普瑞尼亚神经治疗有限公司 | 使用普利多匹定和另一种激活剂治疗肌萎缩侧索的组合疗法 |
| EP4092051A4 (en) * | 2020-06-18 | 2023-09-06 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd | SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE |
| IL301762A (en) | 2020-10-07 | 2023-05-01 | Line 6 Biotechnology Inc | Methods and materials for the treatment of eye diseases |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118290585B (zh) * | 2024-06-04 | 2024-08-30 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd14工程抗体及应用 |
| CN120399098B (zh) * | 2025-07-03 | 2025-09-16 | 上海玄言生物科技有限公司 | 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994028025A1 (en) * | 1993-05-28 | 1994-12-08 | The Scripps Research Institute | Methods and compositions for inhibiting cd14 mediated cell activation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI920450A7 (fi) * | 1989-08-01 | 1992-01-31 | Scripps Clinic And Res Foundation | Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi |
| DE69534601T2 (de) * | 1994-09-16 | 2006-08-03 | The Scripps Research Institute, La Jolla | Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien |
| WO2002042333A1 (en) | 2000-11-22 | 2002-05-30 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| CA2590284A1 (en) | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| US20090181008A1 (en) * | 2005-11-10 | 2009-07-16 | Satoris, Inc. | Methods of treating alzheimer's disease |
| KR101256837B1 (ko) * | 2009-03-09 | 2013-04-22 | 경북대학교 산학협력단 | 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도 |
| JP5894939B2 (ja) * | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| WO2019217916A1 (en) * | 2018-05-10 | 2019-11-14 | The Methodist Hospital | Methods for prognosis and management of disease |
-
2018
- 2018-04-20 CN CN201880040765.4A patent/CN110831975A/zh active Pending
- 2018-04-20 JP JP2020507722A patent/JP2020517740A/ja active Pending
- 2018-04-20 WO PCT/AU2018/050357 patent/WO2018191786A1/en not_active Ceased
- 2018-04-20 EP EP18788123.0A patent/EP3612566A4/en active Pending
- 2018-04-20 US US16/606,727 patent/US20200148780A1/en not_active Abandoned
- 2018-04-20 IL IL270097A patent/IL270097B2/en unknown
- 2018-04-20 KR KR1020197033198A patent/KR20200015477A/ko not_active Ceased
- 2018-04-20 IL IL309046A patent/IL309046B2/en unknown
- 2018-04-20 AU AU2018255489A patent/AU2018255489B2/en active Active
-
2021
- 2021-09-23 US US17/483,517 patent/US12297287B2/en active Active
-
2023
- 2023-04-13 JP JP2023065903A patent/JP2023090751A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994028025A1 (en) * | 1993-05-28 | 1994-12-08 | The Scripps Research Institute | Methods and compositions for inhibiting cd14 mediated cell activation |
Non-Patent Citations (3)
| Title |
|---|
| AXTELLE T, PRIBBLE J., AXTELLE, 31 August 2001 (2001-08-31) * |
| FASSBENDER, K ET AL., FASSBENDER, 3 November 2003 (2003-11-03) * |
| ZHAO, WEIHUA ET AL., ZHAO, 26 July 2015 (2015-07-26) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023090751A (ja) | 2023-06-29 |
| CN110831975A (zh) | 2020-02-21 |
| IL309046A (en) | 2024-02-01 |
| AU2018255489B2 (en) | 2024-06-13 |
| US20220010025A1 (en) | 2022-01-13 |
| AU2018255489A1 (en) | 2019-11-07 |
| EP3612566A1 (en) | 2020-02-26 |
| IL270097B1 (en) | 2024-01-01 |
| IL309046B2 (en) | 2025-03-01 |
| US12297287B2 (en) | 2025-05-13 |
| EP3612566A4 (en) | 2021-03-03 |
| IL270097A (enExample) | 2019-12-31 |
| IL309046B1 (en) | 2024-11-01 |
| JP2020517740A (ja) | 2020-06-18 |
| WO2018191786A1 (en) | 2018-10-25 |
| US20200148780A1 (en) | 2020-05-14 |
| KR20200015477A (ko) | 2020-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12297287B2 (en) | CD14 antagonist antibodies for treating neurodegenerative diseases | |
| KR20230005848A (ko) | 항-trem2 항체의 사용 방법 | |
| US20240102094A1 (en) | Trem2 agonist biomarkers and methods of use thereof | |
| EP3082863B1 (en) | Alpha-enolase specific antibodies and method of use in immune diseases | |
| US20250230228A1 (en) | Methods and agents for the treatment of ocular disease | |
| WO2014100312A1 (en) | Biomarkers for psoriasis treatment response | |
| US10604566B2 (en) | Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis | |
| US20220340687A1 (en) | Methods of treatment using omalizumab | |
| US20250186439A1 (en) | Pyk2 inhibition modulates immune cell function | |
| HK40087465A (zh) | 抗trem2抗体的使用方法 | |
| HK1168112A (en) | Treatment for multiple sclerosis | |
| WO2017183028A1 (en) | Eotaxin-2 inhibitors in the treatment of fibromyalgia |